In contrast to most previous studies, which focused on selected clinical trial populations, this study prospectively evaluated uPA/PAI-1 status as a biomarker in an unselected early breast cancer cohort drawn from daily routine practice. This evidence concerns the gene SERPINE1 and breast carcinoma.